DNLI
Denali Therapeutics Inc
Halal Rating :
Last Price
$21.91
Last updated:
Market Cap
-
7D Change
11.84%
1 Year Change
26.5%
Company Overview
Industries
Exchange
Next Earnings Date
Denali Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company uses its proprietary blood-brain barrier platform technology to develop therapies for conditions such as Alzheimer's disease, Parkinson's disease, and ALS. The company was founded in 2013 and is headquartered in South San Francisco, California.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Denali Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.